The Expressed Genome in Cardiovascular Diseases and Stroke: Refinement, Diagnosis, and Prediction: A Scientific Statement from the American Heart Association

Kiran Musunuru, Erik Ingelsson, Myriam Fornage, Peter Liu, Anne M. Murphy, L. Kristin Newby, Christopher Newton-Cheh, Marco V. Perez, Deepak Voora, Daniel Woo

Research output: Contribution to journalArticle

Abstract

There have been major advances in our knowledge of the contribution of DNA sequence variations to cardiovascular disease and stroke. However, the inner workings of the body reflect the complex interplay of factors beyond the DNA sequence, including epigenetic modifications, RNA transcripts, proteins, and metabolites, which together can be considered the "expressed genome." The emergence of high-throughput technologies, including epigenomics, transcriptomics, proteomics, and metabolomics, is now making it possible to address the contributions of the expressed genome to cardiovascular disorders. This statement describes how the expressed genome can currently and, in the future, potentially be used to diagnose diseases and to predict who will develop diseases such as coronary artery disease, stroke, heart failure, and arrhythmias.

Original languageEnglish (US)
Article numbere000037
JournalCirculation: Cardiovascular Genetics
Volume10
Issue number4
DOIs
StatePublished - Aug 1 2017

Fingerprint

Cardiovascular Diseases
Myocardial Infarction
Genome
Epigenomics
Metabolomics
Proteomics
Cardiac Arrhythmias
Coronary Artery Disease
Heart Failure
Stroke
RNA
Technology
Proteins

Keywords

  • AHA Scientific Statements
  • cardiovascular diseases
  • DNA
  • epigenomics
  • genome
  • metabolomics
  • proteomics
  • stroke

ASJC Scopus subject areas

  • Genetics
  • Cardiology and Cardiovascular Medicine
  • Genetics(clinical)

Cite this

The Expressed Genome in Cardiovascular Diseases and Stroke : Refinement, Diagnosis, and Prediction: A Scientific Statement from the American Heart Association. / Musunuru, Kiran; Ingelsson, Erik; Fornage, Myriam; Liu, Peter; Murphy, Anne M.; Newby, L. Kristin; Newton-Cheh, Christopher; Perez, Marco V.; Voora, Deepak; Woo, Daniel.

In: Circulation: Cardiovascular Genetics, Vol. 10, No. 4, e000037, 01.08.2017.

Research output: Contribution to journalArticle

Musunuru, Kiran ; Ingelsson, Erik ; Fornage, Myriam ; Liu, Peter ; Murphy, Anne M. ; Newby, L. Kristin ; Newton-Cheh, Christopher ; Perez, Marco V. ; Voora, Deepak ; Woo, Daniel. / The Expressed Genome in Cardiovascular Diseases and Stroke : Refinement, Diagnosis, and Prediction: A Scientific Statement from the American Heart Association. In: Circulation: Cardiovascular Genetics. 2017 ; Vol. 10, No. 4.
@article{a63e82b45e4540539acc65cbfdbf53d3,
title = "The Expressed Genome in Cardiovascular Diseases and Stroke: Refinement, Diagnosis, and Prediction: A Scientific Statement from the American Heart Association",
abstract = "There have been major advances in our knowledge of the contribution of DNA sequence variations to cardiovascular disease and stroke. However, the inner workings of the body reflect the complex interplay of factors beyond the DNA sequence, including epigenetic modifications, RNA transcripts, proteins, and metabolites, which together can be considered the {"}expressed genome.{"} The emergence of high-throughput technologies, including epigenomics, transcriptomics, proteomics, and metabolomics, is now making it possible to address the contributions of the expressed genome to cardiovascular disorders. This statement describes how the expressed genome can currently and, in the future, potentially be used to diagnose diseases and to predict who will develop diseases such as coronary artery disease, stroke, heart failure, and arrhythmias.",
keywords = "AHA Scientific Statements, cardiovascular diseases, DNA, epigenomics, genome, metabolomics, proteomics, stroke",
author = "Kiran Musunuru and Erik Ingelsson and Myriam Fornage and Peter Liu and Murphy, {Anne M.} and Newby, {L. Kristin} and Christopher Newton-Cheh and Perez, {Marco V.} and Deepak Voora and Daniel Woo",
year = "2017",
month = "8",
day = "1",
doi = "10.1161/HCG.0000000000000037",
language = "English (US)",
volume = "10",
journal = "Circulation. Genomic and precision medicine",
issn = "1942-325X",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "4",

}

TY - JOUR

T1 - The Expressed Genome in Cardiovascular Diseases and Stroke

T2 - Refinement, Diagnosis, and Prediction: A Scientific Statement from the American Heart Association

AU - Musunuru, Kiran

AU - Ingelsson, Erik

AU - Fornage, Myriam

AU - Liu, Peter

AU - Murphy, Anne M.

AU - Newby, L. Kristin

AU - Newton-Cheh, Christopher

AU - Perez, Marco V.

AU - Voora, Deepak

AU - Woo, Daniel

PY - 2017/8/1

Y1 - 2017/8/1

N2 - There have been major advances in our knowledge of the contribution of DNA sequence variations to cardiovascular disease and stroke. However, the inner workings of the body reflect the complex interplay of factors beyond the DNA sequence, including epigenetic modifications, RNA transcripts, proteins, and metabolites, which together can be considered the "expressed genome." The emergence of high-throughput technologies, including epigenomics, transcriptomics, proteomics, and metabolomics, is now making it possible to address the contributions of the expressed genome to cardiovascular disorders. This statement describes how the expressed genome can currently and, in the future, potentially be used to diagnose diseases and to predict who will develop diseases such as coronary artery disease, stroke, heart failure, and arrhythmias.

AB - There have been major advances in our knowledge of the contribution of DNA sequence variations to cardiovascular disease and stroke. However, the inner workings of the body reflect the complex interplay of factors beyond the DNA sequence, including epigenetic modifications, RNA transcripts, proteins, and metabolites, which together can be considered the "expressed genome." The emergence of high-throughput technologies, including epigenomics, transcriptomics, proteomics, and metabolomics, is now making it possible to address the contributions of the expressed genome to cardiovascular disorders. This statement describes how the expressed genome can currently and, in the future, potentially be used to diagnose diseases and to predict who will develop diseases such as coronary artery disease, stroke, heart failure, and arrhythmias.

KW - AHA Scientific Statements

KW - cardiovascular diseases

KW - DNA

KW - epigenomics

KW - genome

KW - metabolomics

KW - proteomics

KW - stroke

UR - http://www.scopus.com/inward/record.url?scp=85028463876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028463876&partnerID=8YFLogxK

U2 - 10.1161/HCG.0000000000000037

DO - 10.1161/HCG.0000000000000037

M3 - Article

C2 - 28760750

AN - SCOPUS:85028463876

VL - 10

JO - Circulation. Genomic and precision medicine

JF - Circulation. Genomic and precision medicine

SN - 1942-325X

IS - 4

M1 - e000037

ER -